NCT05102136View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 27, 2021

Primary Completion Date

April 4, 2023

Study Completion Date

April 4, 2023

Conditions

Healthy Volunteers

Interventions

DRUG

REGN9933

Administered intravenously (IV) or subcutaneous (SC) per the protocol

DRUG

Placebo

Placebo to match REGN9933 in same form; placebo administered IV or SC per the protocol

Trial Locations (1)

B-2650

Regeneron Study Site, Edegem

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT05102136 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers | Biotech Hunter | Biotech Hunter